AGP Executive Report

No Surprises Act: A federal appeals court sided with providers, striking down parts of the qualifying payment amount formula that payers used to anchor lower payouts in arbitration. Diabetes Care Beyond Clinics: Australia’s Diabetes Australia, Deakin University and Australian Unity will use a new wellbeing index to capture diabetes’s real-world impact on mental health, finances and daily life—not just medical costs. Public Health & Prevention: A new “National Strength Day” aims to normalize strength training for older adults to fight frailty and independence loss. HIV Prevention Gap: Research highlights why women use PrEP far less than men, pointing to clinical, social and structural barriers. Mental Health & Metabolic Risk: A Dutch cohort study links youth antipsychotic starts to a rapid, sustained rise in pharmacologically treated type 2 diabetes risk. Cancer Pipeline Updates: FDA approval of iberdomide (Zenbexus) combos in relapsed/refractory multiple myeloma; phase 3 data support upadacitinib for severe alopecia areata; and zipalertinib plus chemo shows positive interim results in first-line EGFR exon 20 NSCLC. Healthcare Admin Tech: Cotiviti launched an AI coordination-of-benefits tool to reduce enrollment data errors that drive claim disputes.

Vaccine Uptake Gap: A new Merck Canada Pulse Report finds many Canadians aren’t getting key respiratory vaccines and are hesitant to discuss prevention with clinicians ahead of the season. Hypertension Treatment Expansion: Updated US guidance could make nearly 10 million Americans with untreated high blood pressure eligible for medication, shifting decisions toward overall cardiovascular risk. Public Health Risk for Immunotherapy Patients: The CDC warns patients on B-cell–depleting drugs face higher risk of severe arboviral disease and outlines treatment guidance. Cost-Effectiveness Pressure: ICER says AstraZeneca’s new resistant-hypertension drug Baxfendy isn’t cost-effective versus generics at current prices. Healthcare Affordability Debate: India’s private-hospital room price cap proposal is drawing pushback from Apollo, which argues controls could deter capacity and innovation. Digital Health for Metabolic Health: Google adds an insulin-resistance tracker to Pixel Watch/Fitbit using passive sensors and AI trends. Research & Innovation: CN Bio wins an Innovate UK grant to cut animal use in pharmacokinetic studies; Skylark starts dosing a gene-therapy trial for common childhood deafness. Care Delivery & Safety: Ng Teng Fong General Hospital removes ICU sinks to reduce contamination and lower water/energy use.

Vaccine Policy Shock: Trump’s executive order would space childhood shots and split MMR into three single vaccines, with Mississippi and Missouri pediatricians warning it could leave kids vulnerable while autism claims remain unsupported. Gender-Affirming Care Funding: CMS finalized a rule ending federal Medicaid/CHIP funding for puberty blockers, cross-sex hormones, and surgeries for minors (state dollars may still cover), drawing pushback from pediatric groups and raising access concerns for families. Rural AI Pushback: Health leaders are betting on AI “concierge” tools for rural care, but patients and providers worry about uneven results and a widening AI divide. PBM Transparency: FTC settlements with Express Scripts and Caremark are pushing the pharmacy industry toward more pricing and access transparency. Cancer & Biotech Updates: Germline variants may predict CAR T toxicity, and Novo Nordisk’s ziltivekimab failed to cut cardiovascular events in a phase 3 trial. Care Delivery & Wellness: Hims & Hers upgrades women’s health app with AI and a smart scale; a chamomile mouth rinse trial found plaque and gingivitis improvements comparable to chlorhexidine.

BCMA Therapy Sequencing in Myeloma: Real-world data and expert discussion show CAR-T and BCMA bispecifics are often chosen based on patient fitness, prior treatment history, access, and logistics—rather than head-to-head efficacy—highlighting the need for better prospective guidance in relapsed/refractory multiple myeloma. Cancer Disparities: A JAMA Network Open study links socially vulnerable neighborhoods to worse ovarian cancer survival, with a sharper impact for Black women. Hepatitis C Elimination Push: WHO reiterates its 2030 hepatitis elimination targets, while progress depends on diagnosing and moving people into treatment; rapid-clearance regimens like glecaprevir/pibrentasvir support faster care pathways. Drug Supply & Tariffs Risk: Analysts warn Trump’s proposed drug tariffs could disrupt India’s “pharmacy of the world” model, threatening low-cost generics that drive most US prescriptions. Public Health & Safety: UK data shows e-scooter injuries involving children have surged, with few riders wearing helmets; meanwhile, pool safety guidance stresses constant supervision to prevent drownings. Healthcare Costs in India: Private hospitals and NATHEALTH oppose a proposed cap on room charges tied to nearby hotel rates, arguing clinical complexity and staffing drive costs. Biotech & Innovation: CN Bio wins an Innovate UK grant to cut animal use in pharmacokinetic studies using organ-on-a-chip plus modeling; Pharvaris reports progress toward deucrictibant angioedema milestones. Mental Health Policy: India flags postpartum depression as a national policy and screening gap, with calls for structured support for new mothers.

Supply-Chain Risk: Tariffs and Chinese manufacturing dependencies are raising alarms for shortages in lithium batteries, key meds, and filtration systems, with experts urging backup power and 60–90-day stockpiles as price hikes loom. Behavioral Health Access: NOCD says it’s expanding its virtual intensive outpatient therapy for severe OCD nationwide, using exposure and response prevention with step-up/step-down care. Cardiac Safety in the Field: A fast CPR response by a SUNY Upstate medical student helped save a man after cardiac arrest at an airport escalator, underscoring the value of bystander action and AED readiness. Imaging & Diagnostics: Bracco won FDA clearance for a new ultrasound contrast delivery system aimed at more consistent cardiac contrast-enhanced ultrasound exams. Pediatric Allergy Care: New reviews highlight age-specific anaphylaxis signs in infants and toddlers to speed epinephrine use. Policy Shockwaves: A Trump executive order narrows the recommended childhood vaccine schedule to 11 core immunizations and calls for splitting MMR, triggering criticism from medical groups. Rare Disease Funding: U.S. rare disease biotech investment is rebounding after FDA’s Priority Review Voucher renewal, boosting investor confidence. Cardiac CT Insights: Incidental lung findings on CT are linked to higher 3-year mortality after TAVR, pointing to better integrated follow-up.

Supply-Chain Watch: Tariffs and China-linked manufacturing dependencies are raising alarms for shortages in lithium batteries, key meds, and water filtration systems, with experts urging 60–90-day stockpiles and backup power planning as import costs could jump 15–30%. Rural Care Funding: Maryland is set to distribute $80M from federal rural health transformation money to improve access to primary and behavioral care in underserved counties. GLP-1 Safety Scrutiny: UK regulators report 216 suspected GLP-1-related deaths via the Yellow Card system, stressing these are unproven links and calling for careful interpretation as reports surge. Infectious Disease Update: Congo’s Ebola outbreak has surpassed 2,000 deaths, with 4,381 confirmed cases, as insecurity and strained health services complicate response. Clinical Research & Trials: Arch Biopartners expands a Phase II cardiac surgery–associated AKI trial into the U.S.; TB vaccine development advances with M72/AS01E in Phase 3; and early FORWARD cohort results show rapid gains for tanruprubart in Guillain-Barré. Healthcare Business Moves: BMS is investing $2.3B in a Houston manufacturing campus; Cambrex breaks ground on a $30M Milan R&D facility; and Redcliffe Labs expands integrated diagnostics after acquiring Megavision Diagnostics in Pune.

Perioperative Mental Health: A Stanford-led study in Anesthesiology reports a five-step “anesthesia dreaming” protocol that helps patients recall more positive, soothing dreams and boosts satisfaction, with a key element being about 10 minutes of low-stimulation time during emergence. Drug Policy & Access: A U.S. FTC settlement with CVS Caremark spotlights pharmacy benefit manager practices that inflate drug prices via rebates, aiming to redirect billions in savings to patients and push PBMs toward fairer reimbursement. Regulation Shake-Up: Trump’s executive order recommends splitting childhood vaccines into single-disease visits and presses states to narrow school requirements to a smaller federal list, raising major operational questions for primary care. Pharma Dealmaking: Jazz Pharmaceuticals agreed to buy Actio Biosciences for up to $1.32B to expand its epilepsy pipeline, including ABS-1230 for KCNT1-related pediatric epilepsy. Clinical Care Update: A JAMA Otolaryngology trial finds that a short post-tonsillectomy course of oral dexamethasone reduces pain and opioid use in children. Infectious Disease Watch: Suffolk County, New York, confirmed a fourth tularemia (“rabbit fever”) case on Long Island as tick-bite visits hit near-decade highs. Healthcare Innovation: North Carolina and nationwide efforts show AI is being integrated into care workflows, from diagnostics to drafting clinician communications.

Gene Therapy & CAR T Deals: Johnson & Johnson struck a major collaboration with Sail Biomedicines to develop in vivo CAR T for immune-mediated diseases, with up to $3.5B+ in potential value. Regulatory Watch: An FDA advisory panel voted against deramiocel for Duchenne cardiomyopathy, setting up an Aug. 22 decision. Oncology Pipeline: Akeso dosed the first patient in a Phase II trial of AK146D1 (TROP2/Nectin-4 bsADC) plus ivonescimab for advanced breast cancer. Rare Cancer Moves: Sobi added a rare lymphoma drug alliance with Innate Pharma, while Soligenix halted its topical CTCL therapy HyBryte after a Phase III miss. Infectious Disease: WHO urged a Phase III Ervebo vaccine trial against the Bundibugyo Ebola strain in the current outbreak. Healthcare Business: Society of Interventional Radiology launched an initiative to define IR’s value; RadNet reported “disproportionately higher” advanced imaging growth and raised guidance. Global Health & Access: Bangladesh is seeking new markets for pharmaceuticals and other sectors in New Zealand, aiming to diversify beyond garments. Patient Care & Systems: India opened a LE&RN-accredited one-stop lymphedema clinic at Apollo Athenaa.

FDA Narcolepsy Breakthrough: Takeda’s oral orexin agonist oveporexton (Orzeyful) won FDA approval for narcolepsy type 1 in adults, with RMAT designation also highlighted for Aspen Neuroscience’s sasineprocel. Cancer & Cell Therapy Debate: New discussion questions whether CAR T outcomes are shaped by patient selection, and how that affects evidence for earlier use in multiple myeloma. GLP-1 Cardiovascular Data: Database-backed findings suggest tirzepatide initiation in type 2 diabetes with ASCVD may lower major adverse cardiovascular events versus placebo proxy. Healthcare Access & Costs: A report on the ACA claims fraud drove enrollment drops, while critics point to higher premiums and deductibles leaving millions uninsured. Mental Health Services: UK mental health charities warn Northern Ireland’s strategy remains underfunded despite new UK crisis-service investment. Public Health Equity: WHO-linked analysis estimates heavy hepatitis B mother-to-child transmission in Africa and calls for higher birth-dose vaccination plus maternal antivirals. Rural Care Pressure: A commentary argues kidney value-based care hasn’t reduced hospital spending, and that the cost-driving hospitalization happens earlier than targets. Patient Safety in Practice: A study finds standard clinic schedules can push working patients out of outpatient alcohol recovery. Industry Watch: RadNet posted record quarterly revenue and guidance updates, while Depo-Provera litigation continues to grow over alleged safety warnings.

Medicine Access & Pricing: South Africa’s pharma industry warns of growing medicine shortages as regulated prices and rising costs squeeze manufacturers, with oil-price-linked cost pressure cited. Diabetes Affordability Policy: A U.S. bill (INSULIN Act) advances to cap private-insurance insulin at $35/month and targets alleged FDA citizen-petition tactics that can delay cheaper generics and biosimilars. Pharma Supply & Quality: Maharashtra FDA permanently cancels a Pune pharma firm’s licence after serious GMP lapses tied to six contaminated medicines. Diabetes Drug Competition: A Canadian-made generic Ozempic is poised to enter the market, aiming to boost local pharmaceutical sovereignty. Cancer Care: Phase 3 PSMAddition results show lutetium Lu 177 vipivotide tetraxetan added to standard therapy extends radiographic progression-free survival in PSMA-positive metastatic prostate cancer. Health Tech & AI: India’s health ministry releases an AI in MedTech knowledge paper outlining priorities to move AI from pilots to clinical scale, including data fragmentation and regulation. Public Health Systems: Nigeria’s NPHCDA maps “zero-dose” child hotspots to target immunisation outreach using an identify-enumerate-vaccinate approach. Wellness & Nutrition: New reporting highlights practical habits for steadier blood sugar, plus fermented drinks’ potential benefits and label/sugar caveats. Mental Health: Spokane wildfire coverage spotlights the mental health impact of smoke, shock, and “survival mode” after disasters. Research Advances: Studies link earlier allergen introduction to falling peanut allergy rates and explore dementia types via distinct immune inflammation patterns.

Dementia & Inflammation: A new meta-analysis links four common dementia types to distinct immune/inflammatory profiles, raising hopes for more targeted treatments. Public Health Access: Nigeria’s NPHCDA mapped “zero-dose” hotspots to guide targeted vaccination using an identify-enumerate-vaccinate approach. Drug Pricing & Patents: U.S. lawmakers advanced insulin cost caps ($35/month) and moved to curb FDA citizen-petition tactics that can delay generics and biosimilars. New Narcolepsy Option: The FDA approved Orzeyful (oveporexton), the first medicine aimed at treating the full symptom range of narcolepsy type 1 by restoring orexin signaling. Food Allergy Breakthrough: A study suggests omalizumab-facilitated oral immunotherapy can help many multi-food allergy patients start at maintenance dosing with fewer escalation steps. Gut Microbiome Therapy: Early results from “poop pill” fecal transplants indicate some severe peanut-allergy patients may gain tolerance, with antibiotics potentially improving transfer. Women’s Health: Research found type 2 diabetes is tied to more severe menopause symptoms, underscoring the need to manage cardiovascular risk during the transition. Care Delivery & Equity: Experts discuss how to expand access to bladder-sparing intravesical therapies despite logistical and reimbursement barriers.

FDA Watch: Moderna’s mRNA flu vaccine mFlusiva wins FDA approval for adults 50+, but trial data show higher Grade 3 reactions and only a narrow hospitalization benefit. Public Health: The CDC says the cyclospora outbreak tied to iceberg lettuce has expanded to 15 states, with nearly 6,400 illnesses reported and far higher counts suggested by local data. Healthcare Tech: Onvida Health earns KLAS recognition for improving electronic health record workflows, aiming to reduce clinician burnout by streamlining documentation. Policy & Access: CMS released an implementation timeline for No Surprises Act independent dispute resolution updates, clarifying timelines and coding details. Drugs & Litigation: The Ozempic lawsuit crisis keeps growing, with nearly 4,000 cases consolidated in MDL over alleged inadequate side-effect warnings. Nutrition & Wellness: WK Kellogg accelerates plans to remove artificial colors and BHT from cereals by end of 2026, shifting to natural-derived colors. Community Care: Leicester’s mental health overhaul includes a new emergency department for people in crisis plus more walk-in community centers. Digital Health in India: Ayushman Bharat’s Scan and Register service tops 25 crore OPD registrations via QR-based sharing of ABHA profiles.

Bladder Cancer Care: AHN is rolling out Inlexzo (formerly TAR-200), an indwelling gemcitabine system designed to extend local drug exposure for BCG-unresponsive NMIBC while avoiding systemic toxicity. Pediatric Oncology: A 5-year ELIANA analysis shows durable, manageable long-term results for tisagenlecleucel in pediatric/young adult B-ALL. CAR T Decision-Making: Experts discuss why early referral and careful patient selection matter in multiple myeloma, and how sequencing CAR T before bispecifics may improve outcomes. End-of-Life Access: Vancouver Coastal Health is reopening Cottage Hospice with upgrades and a new operating partnership to meet ongoing demand for palliative care. Pediatric Allergy Screening: Symptom-based screening in children with asthma found unexpectedly high eosinophilic esophagitis rates, supporting earlier evaluation. Healthcare Workforce Burnout: Cardiac CT specialist burnout is worsening, with calls for structural fixes beyond individual resilience. Pharma Deals & Delivery: Tarsus will acquire Alkeus for $450M to advance a Stargardt therapy; Amazon Pharmacy begins $50/month GLP-1 delivery for eligible Medicare patients. Public Health & Safety: A study flags high severe-disease risk among hospitalized children with acute respiratory tract infections, especially after transfers. Opioid Misuse Economics: A University of Utah evaluation finds mindfulness-based MORE could be highly cost-effective for opioid misuse and chronic pain.

Psychedelic PTSD Care: A new study finds high-dose psilocybin sessions for PTSD are mostly spent in silence, suggesting support is often quiet presence rather than talk therapy. Neurodegeneration in Psychosis: PET imaging links late-onset psychosis to tau buildup, pointing to hidden brain differences that may explain why symptoms vary. ADHD Medication Aftereffects: Stopping methylphenidate can disrupt sleep and activity rhythms long after discontinuation in animal research. Cancer Therapy Milestone: Replimune’s oncolytic virus therapy wins FDA approval for advanced melanoma with Opdivo, after prior setbacks. Immunotherapy Research: Zebrafish work ties gene-activity changes to spinal disc breakdown, hinting at future drug targets for back pain. Care Delivery & Staffing: Nurses protest CommonSpirit Health cuts tied to “safe births,” while a UK hospital phlebotomy team is honored for compassionate patient care. Food & Health Safety: Nigeria police step up efforts to curb sale of dead animals’ meat; separate reporting flags microplastics in blood as linked to severe heart attacks, though causation isn’t proven. Industry & Policy: The UK expands its Global Talent visa to over 100 research-focused companies, and new U.S. generic drug tariff rules are set to reshape pharma sourcing and manufacturing plans.

FDA & Vaccines: Moderna’s first mRNA flu vaccine for adults 50+ (mFlusiva) won FDA approval, adding a new option for seniors as flu hospitalizations stay high. Oncology Advances: MonumenTAL-6 data highlight a major risk reduction with teclistamab plus talquetamab in relapsed/refractory multiple myeloma, while FDA cleared Replimune (Tudriqev) with Opdivo for advanced melanoma after prior setbacks. Tech in Care: A small UC San Diego study found Apple Vision Pro could cut endoscopic tear-duct surgery time by about 19% and reduce surgeon workload. Policy & Access: CMS’s Medicaid work requirements rule sets a nationwide “community engagement” framework, but states will vary on exemptions and verification. Health Systems & Safety: Shared cardiac PET programs may expand access, and RFID tracking is being pitched to close hospital medication inventory gaps. Public Health Watch: Cyclospora investigations expanded across more states, with CDC-linked guidance urging caution with certain raw produce. Business Moves: Biogen completed its RayThera acquisition to bolster immunology assets.

Regulatory Overhaul (Medical Cannabis): The Bahamas is moving ahead with medical cannabis after signing with Metrc for a digital “seed-to-sale” tracking and licensing platform, plus e-prescription updates via an amended Pharmacy Act. FDA & Vaccines: Moderna’s mRNA seasonal flu vaccine (mFlusiva) is approved for adults 50+ in the U.S., with a faster, more flexible manufacturing path for future strains. RSV Prevention Expansion: The FDA accepted Merck’s sBLA to expand ENFLONSIA (clesrovimab-cfor) to prevent RSV lower respiratory tract disease in children under two at increased risk for their second season. Nephrology Treatment Shift: New discussion weighs where corticosteroids and RAS inhibitors fit now that sparsentan is FDA-approved for FSGS, including how it may displace RAS inhibitors for proteinuria reduction. Oncology Trial Momentum: Summit Therapeutics starts the global phase 2/3 HARMONi-GU1 trial testing ivonescimab plus enfortumab vedotin as first-line urothelial cancer therapy. Healthcare Operations & Safety: OhioHealth plans a $10.2M expansion doubling CT capacity, while interventional teams release an ALARA radiation-safety toolkit to reduce occupational exposure. Pharma Compliance Crackdown: India’s drug rules now let state authorities debar companies submitting fake or misleading data, with due process built in.